Integrating CRISPR genome editing with liver organoid and hiPSC-derived microfluidic platforms to model metabolic dysfunction-associated steatotic liver disease
{{output}}
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), arise from the interplay of genetic susceptibility, metabolic stress, and multicellular hepatic dysfunction. How... ...
